Cotrimoxazole prophylaxis decreases tuberculosis risk among Asian patients with HIV.

ABSTRACT: INTRODUCTION:Cotrimoxazole (CTX) is recommended as prophylaxis against Pneumocystis jiroveci pneumonia, malaria and other serious bacterial infections in HIV-infected patients. Despite its in vitro activity against Mycobacterium tuberculosis, the effects of CTX preventive therapy on tuberculosis (TB) remain unclear. METHODS:Adults living with HIV enrolled in a regional observational cohort in Asia who had initiated combination antiretroviral therapy (cART) were included in the analysis. Factors associated with new TB diagnoses after cohort entry and survival after cART initiation were analysed using Cox regression, stratified by site. RESULTS:A total of 7355 patients from 12 countries enrolled into the cohort between 2003 and 2016 were included in the study. There were 368 reported cases o

SUBMITTER: Ku SW 

PROVIDER: S-EPMC6439318 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature